The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
Abstract Background The management of Acute Myeloid Leukemia (AML) during pregnancy remains challenging as both the maternal and fetal outcomes should be considered. Several reports suggested that chemotherapy can be administered safely during the second and third trimester of pregnancy. However, th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-10-01
|
| Series: | BMC Pregnancy and Childbirth |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12884-019-2522-1 |
| _version_ | 1818348589575831552 |
|---|---|
| author | Abdullah M. Alrajhi Sarah A. Alhazzani Nouf M. Alajaji Fouad H. Alnajjar Nawal F. Alshehry Imran K. Tailor |
| author_facet | Abdullah M. Alrajhi Sarah A. Alhazzani Nouf M. Alajaji Fouad H. Alnajjar Nawal F. Alshehry Imran K. Tailor |
| author_sort | Abdullah M. Alrajhi |
| collection | DOAJ |
| description | Abstract Background The management of Acute Myeloid Leukemia (AML) during pregnancy remains challenging as both the maternal and fetal outcomes should be considered. Several reports suggested that chemotherapy can be administered safely during the second and third trimester of pregnancy. However, the use of 5-azacytidine presents limitation due to lack of data. Case presentation A 28-years-old woman in the 26th week of gestation diagnosed with FLT3/ITD-mutated AML, complete remission was induced by Daunorubicin and Cytarabine, and subsequently with 5-azacytidine (75 mg/m2 daily for 7 days) with no fetal hematological or toxicity issues. Fetal ultrasound showed no aberrant morphology. Fetal size below the 5th percentile with normal umbilical artery dopplers, normal middle cerebral artery dopplers and ductus venosus doppler. Three weeks post 5-azacytidine, the team determined the most appropriate time for delivery after balancing the risks of prematurity and prevention of disease relapse since patient in hematological remission. The patient underwent elective lower segment caesarian section and had a baby girl delivered at 35 weeks of gestation weighing 1670 g without apparent anomalies. Conclusion Treatment using 5-azacytadine during last trimester of pregnancy resulted in no major fetal and maternal complications. These findings concluded that 5-azacytadine during the third trimester of pregnancy seems to be safe however, potential risks of this agent should be considered. |
| first_indexed | 2024-12-13T17:52:28Z |
| format | Article |
| id | doaj.art-aa1f3223b73d4324b5d077891e996062 |
| institution | Directory Open Access Journal |
| issn | 1471-2393 |
| language | English |
| last_indexed | 2024-12-13T17:52:28Z |
| publishDate | 2019-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pregnancy and Childbirth |
| spelling | doaj.art-aa1f3223b73d4324b5d077891e9960622022-12-21T23:36:27ZengBMCBMC Pregnancy and Childbirth1471-23932019-10-011911410.1186/s12884-019-2522-1The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case reportAbdullah M. Alrajhi0Sarah A. Alhazzani1Nouf M. Alajaji2Fouad H. Alnajjar3Nawal F. Alshehry4Imran K. Tailor5Department of Pharmacy, King Fahad Medical CityDepartment of Pharmacy, King Fahad Medical CityMaternal Fetal Medicine Department, King Fahad Medical CityDepartment of Pharmacy, King Fahad Medical CityComprehensive Cancer Center, King Fahad Medical CityComprehensive Cancer Center, King Fahad Medical CityAbstract Background The management of Acute Myeloid Leukemia (AML) during pregnancy remains challenging as both the maternal and fetal outcomes should be considered. Several reports suggested that chemotherapy can be administered safely during the second and third trimester of pregnancy. However, the use of 5-azacytidine presents limitation due to lack of data. Case presentation A 28-years-old woman in the 26th week of gestation diagnosed with FLT3/ITD-mutated AML, complete remission was induced by Daunorubicin and Cytarabine, and subsequently with 5-azacytidine (75 mg/m2 daily for 7 days) with no fetal hematological or toxicity issues. Fetal ultrasound showed no aberrant morphology. Fetal size below the 5th percentile with normal umbilical artery dopplers, normal middle cerebral artery dopplers and ductus venosus doppler. Three weeks post 5-azacytidine, the team determined the most appropriate time for delivery after balancing the risks of prematurity and prevention of disease relapse since patient in hematological remission. The patient underwent elective lower segment caesarian section and had a baby girl delivered at 35 weeks of gestation weighing 1670 g without apparent anomalies. Conclusion Treatment using 5-azacytadine during last trimester of pregnancy resulted in no major fetal and maternal complications. These findings concluded that 5-azacytadine during the third trimester of pregnancy seems to be safe however, potential risks of this agent should be considered.http://link.springer.com/article/10.1186/s12884-019-2522-1“5-azacyitidneAcute Myeloid leukemiapregnancythird trimesterDaunorubicinCytarabine |
| spellingShingle | Abdullah M. Alrajhi Sarah A. Alhazzani Nouf M. Alajaji Fouad H. Alnajjar Nawal F. Alshehry Imran K. Tailor The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report BMC Pregnancy and Childbirth “5-azacyitidne Acute Myeloid leukemia pregnancy third trimester Daunorubicin Cytarabine |
| title | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report |
| title_full | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report |
| title_fullStr | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report |
| title_full_unstemmed | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report |
| title_short | The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report |
| title_sort | use of 5 azacytidine in pregnant patient with acute myeloid leukemia aml a case report |
| topic | “5-azacyitidne Acute Myeloid leukemia pregnancy third trimester Daunorubicin Cytarabine |
| url | http://link.springer.com/article/10.1186/s12884-019-2522-1 |
| work_keys_str_mv | AT abdullahmalrajhi theuseof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT sarahaalhazzani theuseof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT noufmalajaji theuseof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT fouadhalnajjar theuseof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT nawalfalshehry theuseof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT imranktailor theuseof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT abdullahmalrajhi useof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT sarahaalhazzani useof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT noufmalajaji useof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT fouadhalnajjar useof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT nawalfalshehry useof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport AT imranktailor useof5azacytidineinpregnantpatientwithacutemyeloidleukemiaamlacasereport |